SIGA - SIGAテクノロジ―ズ (SIGA Technologies Inc.) SIGAテクノロジ―ズ

 SIGAのチャート


 SIGAの企業情報

symbol SIGA
会社名 SIGA Technologies Inc (SIGAテクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エスアイジーエー・テクノロジー(SIGA Technologies Inc.)は天然痘、エボラ出血熱、デング熱、ラッサ熱とその他の危険なウイルスにあるいくつかの致命的な病気による病原体のための製薬ソリューションの開発・商業化を中心に行う製薬会社。同社は優先度の高い脅威を防止・治療するための薬品の発見、開発、製造と商業化を行う。同社は主に恐ろしいウイルス性疾患の武装を解除し、堅牢で現代的な生体防御対策を作成する。同社の製品「ST-246」はオルソポックスウイルスをターゲットとする経口で投与される抗ウイルス剤。平成23年5月13日、同社は戦略備蓄に200万コースの「ST-246」を提供する合意に基づいてBARDA契約を締結した。   SIGAテクノロジ―ズは、米国の医薬品会社。満たされていない医療ニ―ズとバイオの脅威へのソリュ―ションの開発、商品化に注力する。主要製品は、オルソポックスウイルスをタ―ゲットにした経口投与型抗ウイルス薬「Arestvyr (別名ST-246)」である。このほか、デング熱抗ウイルス薬および抗アレナウイルス薬の製品候補がある。   SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Its lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a stockpile of 1.7 million oral courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox on July 13, 2018. In September 2018, SIGA signed a contract with Biomedical Advanced Research and Development Authority (BARDA) for additional procurement and development related to both oral and intravenous formulations of TPOXX.
本社所在地 31 East 62nd Street New York NY 10065 USA
代表者氏名 Eric A. Rose エリックA.ローズ
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 212-672-9100
設立年月日 35034
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 37人
url www.siga.com
nasdaq_url https://www.nasdaq.com/symbol/siga
adr_tso
EBITDA EBITDA(百万ドル) -17.45037
終値(lastsale) 5.53
時価総額(marketcap) 437755120.74
時価総額 時価総額(百万ドル) 401.34150
売上高 売上高(百万ドル) 7.21176
企業価値(EV) 企業価値(EV)(百万ドル) 464.04087
当期純利益 当期純利益(百万ドル) -41.45262
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 SIGA Technologies Inc. revenues decreased 53% to $4.4M. Net loss increased 16% to $18.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects GAIN increase from $332K to $2.9M (expense) Interest expense increase of 5% to $7.6M (expense) Selling general and administrative remaining flat at $5.9M (expense).

 SIGAのテクニカル分析


 SIGAのニュース

   SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®  2021/09/13 11:30:00 Intrado Digital Media
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of a procurement option under its 75A50118C00019 (19C) contract with Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the delivery of oral TPOXX ® treatment courses valued at approximately $112.5 million to the U.S. government. Product deliveries in connection with the option exercise are targeted for 2021.
   SIGA Technologies hits four month-high as BARDA extends contract for smallpox antiviral  2021/09/09 17:50:16 Seeking Alpha
   SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021  2021/09/07 17:16:50 Benzinga
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company''s Chief Executive Officer, will be a speaker at the NCT USA conference on September 8, in Baltimore, Maryland. Dr. Gomez will be giving a presentation "Antiviral Drugs: Adapting Capabilities for an Effective Response to Future Epidemic Outbreaks" and will join a panel with leadership from Health and Human Services and the Department of Defense to discuss future pandemic preparedness. "As we begin to understand the lessons learned from COVID-19, we are reminded that antiviral drugs are challenging to develop, but critical to any pandemic preparedness plan," said Dr. Gomez. "TPOXX® is an incredible case study in development and deployment of an antiviral drug for smallpox, and we are working to expand regulatory approvals for additional orthropox viruses and post-exposure prophylactic use. Preparedness is more efficient and saves lives relative to response, and robust stockpiling of products like TPOXX is important to ensure outbreaks do not rapidly spiral out of control.
   SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021  2021/09/07 17:16:00 Intrado Digital Media
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Companys Chief Executive Officer, will be a speaker at the NCT USA conference on September 8, in Baltimore, Maryland.
   SIGA Technologies - Q221 results  2021/08/10 11:58:00 FinanzNachrichten
SIGA recently reported Q221 results, which featured $6.9m of revenue for the delivery of oral TPOXX to the Public Health Agency of Canada (PHAC). SIGA continues to work towards finalizing an order

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 SIGAテクノロジ―ズ SIGA SIGA Technologies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)